Cited by 521Genomics and Chromatin DynamicsCancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 200 of the 201 references it cites were found in a registry or an index.

MYC: connecting selective transcriptional control to global RNA production

Kress, Theresia R., Sabò, Arianna, Amati, Bruno·2015·Nature reviews. Cancer

Open this paper in CoChat — free account

Abstract

Two opposing models have been proposed to describe the function of the MYC oncoprotein in shaping cellular transcriptomes: one posits that MYC amplifies transcription at all active loci; the other that MYC differentially controls discrete sets of genes, the products of which affect global transcript levels. Here, we argue that differential gene regulation by MYC is the sole unifying model that is consistent with all available data. Among other effects, MYC endows cells with physiological and metabolic changes that have the potential to feed back on global RNA production, processing and turnover. The field is progressing steadily towards a full characterization of the MYC-regulated genes and pathways that mediate these biological effects and - by the same token - endow MYC with its pervasive oncogenic potential.

Integrity signals

Registry

Crossref · 10.1038/nrc3984

Cites

200 of 200 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism through the eIF4B-Dependent Control of c-Myc Translation
Csibi, A., Lee, G., Yoon, S.-O., Tong, H., Ilter, D., Elia, I., Fendt, S., Roberts, T. M., & Blenis, J. (2014) · Current Biology · doi:10.1016/j.cub.2014.08.007 · Cited by 253
Retracted
Molecular Cell Biology
Lodish, H. F. (1986) · Cited by 5,650
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
MYC on the Path to Cancer
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
CpG islands and the regulation of transcription
Deaton, A. M., & Bird, A. (2011) · Genes & Development · doi:10.1101/gad.2037511 · Cited by 3,187
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Stat3 as an Oncogene
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation
Wang, R., Dillon, C. P., Shi, L. Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L. L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.021 · Cited by 2,140
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001

Show all 201 references

Sorted by citations

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 1,044
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
Robertson, A. G., Shih, J., Yau, C. S. F., Gibb, E. A., Oba, J., Mungall, K. L., Hess, J. M., Uzunangelov, V., Walter, V., Danilova, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.003 · Cited by 908
The role of ubiquitination in tumorigenesis and targeted drug discovery
Deng, L., Meng, T., Chen, L., Wei, W., & Wang, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0107-0 · Cited by 744
Stem cell programs in cancer initiation, progression, and therapy resistance
Huang, T., Song, X., Xu, D., Tiek, D., Goenka, A., Wu, B., Sastry, N., Hu, B., & Cheng, S.-Y. (2020) · Theranostics · doi:10.7150/thno.41648 · Cited by 524
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
FBXW7: a critical tumor suppressor of human cancers
Yeh, C., Bellon, M., & Nicot, C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0857-2 · Cited by 525
lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer
Wang, Z., Yang, B., Zhang, M., Guo, W., Wu, Z., Wang, Y., Jia, L., Li, S., Johnson, R., Demchok, J. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.006 · Cited by 473
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Han, H., Jain, A. D., Truica, M. I., Izquierdo-Ferrer, J., Anker, J. F., Lysy, B., Sagar, V., Luan, Y., Chalmers, Z. R., Unno, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.001 · Cited by 479
Promoter of lncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element
Cho, S. W., Xu, J., Sun, R., Mumbach, M. R., Carter, A. C., Chen, Y. G., Yost, K. E., Kim, J., He, J., Nevins, S. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.068 · Cited by 459
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Schaub, F. X., Dhankani, V., Berger, A. C., Trivedi, M., Richardson, A. B., Shaw, R., Zhao, W., Zhang, X., Ventura, A., Liu, Y., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.03.003 · Cited by 431
“Pan-cancer Canonical and Non-canonical MYC-Speciﬁc Gene Set Enrichment Alteration of MYC expression leads to broad transcriptional changes through both direct and indirect effects, as observed in many experimental systems (as reviewed in Kress et al., 2015).”
Lipid metabolism in cancer progression and therapeutic strategies
Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., Yang, J., Zheng, Y., Bruns, C. J., Zhao, Y., et al. (2020) · MedComm · doi:10.1002/mco2.27 · Cited by 428
The role of enhancers in cancer
Sur, I., & Taipale, J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.62 · Cited by 393
SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis
Muhar, M., Ebert, A., Neumann, T., Umkehrer, C., Jude, J., Wieshofer, C., Rescheneder, P., Lipp, J., Herzog, V. A., Reichholf, B., et al. (2018) · Science · doi:10.1126/science.aao2793 · Cited by 371
Target gene-independent functions of MYC oncoproteins
Baluapuri, A., Wolf, E., & Eilers, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0215-2 · Cited by 310
The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis
Carroll, P. A., Freie, B. W., Mathsyaraja, H., & Eisenman, R. N. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0650-z · Cited by 289
LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis
Hua, Q., Jin, M., Mi, B., Xu, F., Li, T. X., Zhao, L., Liu, J., & Huang, G. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0773-y · Cited by 263
Transcriptomic and proteomic landscape of mitochondrial dysfunction reveals secondary coenzyme Q deficiency in mammals
Kühl, I., Miranda, M., Atanassov, I., Kuznetsova, I., Hinze, Y., Mourier, A., Filipovska, A., & Larsson, N. (2017) · eLife · doi:10.7554/elife.30952 · Cited by 261
The Expanding World of N-MYC–Driven Tumors
Rickman, D. S., Schulte, J. H., & Eilers, M. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0273 · Cited by 246
MYC and tumor metabolism: chicken and egg
Dejure, F. R., & Eilers, M. (2017) · The EMBO Journal · doi:10.15252/embj.201796438 · Cited by 240
Interleukin-1β Activates a MYC-Dependent Metabolic Switch in Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis
Lemos, D. R., McMurdo, M., Karaca, G., Wilflingseder, J., Leaf, I. A., Gupta, N. R., Miyoshi, T., Susa, K., Johnson, B. G., Soliman, K., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121283 · Cited by 220
Opposing macrophage polarization programs show extensive epigenomic and transcriptional cross-talk
Piccolo, V., Curina, A., Genua, M., Ghisletti, S., Simonatto, M., Sabò, A., Amati, B. B., Ostuni, R., & Natoli, G. (2017) · Nature Immunology · doi:10.1038/ni.3710 · Cited by 216
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
Beaulieu, M.-È., Jauset, T., Massó-Vallés, D., Martínez-Martín, S., Rahl, P. B., Maltais, L., Fluck, M. F. Z., Casacuberta‐Serra, S., del Pozo, E. S., Fiore, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aar5012 · Cited by 212
Oncogenic MYC Activates a Feedforward Regulatory Loop Promoting Essential Amino Acid Metabolism and Tumorigenesis
Yue, M., Jiang, J., Gao, P., Liu, H., & Qing, G. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.12.002 · Cited by 201
Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors
Richards, M. W., Burgess, S. G., Poon, E., Carstensen, A., Eilers, M., Chesler, L., & Bayliss, R. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610626113 · Cited by 189
MYC—Master Regulator of the Cancer Epigenome and Transcriptome
Poole, C. J., & van Riggelen, J. (2017) · Genes · doi:10.3390/genes8050142 · Cited by 180
c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment
Gao, F., Li, X.-T., Xu, K., Wang, R., & Guan, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01043-1 · Cited by 181
Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer
Yang, X., Ye, T., Liu, H., Lv, P., Duan, C., Wu, X., Jiang, K., Lu, H., Ding, X., Peng, E., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01300-8 · Cited by 169
Functionally diverse human T cells recognize non-microbial antigens presented by MR1
Lepore, M., Kalinichenko, A., Calogero, S., Kumar, P., Paleja, B. S., Schmaler, M., Narang, V., Zolezzi, F., Poidinger, M., Mori, L., et al. (2017) · eLife · doi:10.7554/elife.24476 · Cited by 169
Biophysical properties of AKAP95 protein condensates regulate splicing and tumorigenesis
Li, W., Hu, J., Shi, B., Palomba, F., Digman, M. A., Gratton, E., & Jiang, H. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0550-8 · Cited by 158
Different promoter affinities account for specificity in MYC-dependent gene regulation
Lorenzin, F., Benary, U., Baluapuri, A., Walz, S., Jung, L. A., von Eyß, B., Kisker, C., Wolf, J., Eilers, M., & Wolf, E. (2016) · eLife · doi:10.7554/elife.15161 · Cited by 165
Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC
Boike, L., Cioffi, A. G., Majewski, F. C., Co, J., Henning, N. J., Jones, M. D., Liu, G., McKenna, J. M., Tallarico, J. A., Schirle, M., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.09.001 · Cited by 154
BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis
Richart, L., Pau, E. C. D. S., Rio‐Machín, A., de Andrés, M. P., Cigudosa, J. C., Lobo, V. J. S.-A., & Real, F. X. (2016) · Nature Communications · doi:10.1038/ncomms10153 · Cited by 155
Pluripotency and the origin of animal multicellularity
(2019) · doi:10.1038/s41586-019-1290-4 · Cited by 146
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 150
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling
Zimmerli, D., Brambillasca, C. S., Talens, F., Bhin, J., Linstra, R., Romanens, L., Bhattacharya, A., Joosten, S. E. P., Silva, A. M. D., Padrão, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34000-6 · Cited by 163
More than just scanning: the importance of cap-independent mRNA translation initiation for cellular stress response and cancer
Lacerda, R., Menezes, J., & Romão, L. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2428-2 · Cited by 150
The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer
Lancho, O., & Herranz, D. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.10.003 · Cited by 143
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer
Zeng, Z., Fu, M., Hu, Y., Wei, Y., Wei, X., & Luo, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01877-w · Cited by 155
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
Struntz, N. B., Chen, A., Deutzmann, A., Wilson, R. M., Stefan, E., Evans, H. L., Ramirez, M. A., Liang, T., Caballero, F., Wildschut, M. H. E., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.02.009 · Cited by 130
MYC Recruits SPT5 to RNA Polymerase II to Promote Processive Transcription Elongation
Baluapuri, A., Hofstetter, J., Dudvarski Stankovic, N., Endres, T., Bhandare, P., Vos, S. M., Adhikari, B., Schwarz, J. D., Narain, A., Vogt, M., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.02.031 · Cited by 138
Concise Review: Control of Cell Fate Through Cell Cycle and Pluripotency Networks
Boward, B., Wu, T., & Dalton, S. (2016) · Stem Cells · doi:10.1002/stem.2345 · Cited by 147
Advances in targeted therapy for malignant lymphoma
Wang, L., Qin, W. D., Huo, Y., Li, X., Shi, Q., Rasko, J. E. J., Janin, A., & Zhao, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0113-2 · Cited by 146
Proteomic profiling of VCP substrates links VCP to K6‐linked ubiquitylation and c‐Myc function
Heidelberger, J. B., Voigt, A., Borisova, M. E., Petrosino, G., Ruf, S., Wagner, S., & Beli, P. (2018) · EMBO Reports · doi:10.15252/embr.201744754 · Cited by 142
Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc
Wang, J., Yang, Y., Shao, F., Meng, Y., Guo, D. S., He, J., & Lu, Z. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01037-4 · Cited by 144
Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma
Chen, D., Zhao, Z., Huang, Z., Chen, D.-C., Zhu, X., Wang, Y., Yan, Y., Tang, S., Madhavan, S., Ni, W., et al. (2018) · Bone Research · doi:10.1038/s41413-018-0009-8 · Cited by 135
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy
Abbas, H. A., Hao, D., Tomczak, K. J., Barrodia, P., Im, J. S., Reville, P. K., Alaniz, Z., Wang, W., Wang, R., Wang, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26282-z · Cited by 130
Targeting MYC in multiple myeloma
Jovanović, K., Roche‐Lestienne, C., Ghobrial, I. M., Facon, T. T. F., Quesnel, B., & Manier, S. (2018) · Leukemia · doi:10.1038/s41375-018-0036-x · Cited by 133
A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation
Castell, A., Yan, Q., Fawkner, K., Hydbring, P., Zhang, F., Verschut, V., Franco, M., Zakaria, S. M., Bazzar, W., Goodwin, J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28107-4 · Cited by 130
DAXX in cancer: phenomena, processes, mechanisms and regulation
Mahmud, I., & Liao, D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz634 · Cited by 122
MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis
Tu, W. B., Shiah, Y.-J., Lourenco, C., Mullen, P. J., Dingar, D. D., Redel, C., Tamachi, A., Ba-Alawi, W., Aman, A. M., Al‐awar, R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.001 · Cited by 119
Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis
Andrews, F. H., Singh, A. R., Joshi, S., Smith, C. A., Morales, G. A., Garlich, J. R., Durden, D. L., & Kutateladze, T. G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613091114 · Cited by 119
The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number
Lavado, A., Park, J. Y., Paré, J., Finkelstein, D., Pan, H., Xu, B., Fan, Y., Kumar, R. P., Neale, G. A. M., Kwak, Y. D., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.09.021 · Cited by 119
MYU, a Target lncRNA for Wnt/c-Myc Signaling, Mediates Induction of CDK6 to Promote Cell Cycle Progression
Kawasaki, Y., Komiya, M., Matsumura, K., Negishi, L., Suda, S., Okuno, M., Yokota, N., Osada, T., Nagashima, T., Hiyoshi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.015 · Cited by 114
Ubiquitin-Dependent Turnover of MYC Antagonizes MYC/PAF1C Complex Accumulation to Drive Transcriptional Elongation
Jaenicke, L. A., von Eyß, B., Carstensen, A., Wolf, E., Xu, W., Greifenberg, A. K., Geyer, M., Eilers, M., & Popov, N. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.11.007 · Cited by 113
MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels
Lu, Y., Hu, Z., Mangala, L. S., Stine, Z. E., Hu, Z., Jiang, D., Xiang, Y., Zhang, Y., Pradeep, S., Rodriguez‐Aguayo, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0815 · Cited by 111
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Li, W., Gupta, S. K., Han, W., Kundson, R. A., Nelson, S., Knutson, D. L., Greipp, P. T., Elsawa, S. F., Sotomayor, E. M., & Gupta, M. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0761-2 · Cited by 109
Single-molecule footprinting identifies context-dependent regulation of enhancers by DNA methylation
Kreibich, E., Kleinendorst, R., Barzaghi, G., Kaspar, S., & Krebs, A. R. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.017 · Cited by 106
OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors
Jung, L. A., Gebhardt, A., Koelmel, W., Ade, C. P., Walz, S., Kuper, J., von Eyss, B., Letschert, S., Redel, C., d'Artista, L., et al. (2017) · Oncogene · doi:10.1038/onc.2016.354 · Cited by 101
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 104
Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability
Iwai, K., Yaguchi, M., Nishimura, K., Yamamoto, Y., Tamura, T., Nakata, D., Dairiki, R., Kawakita, Y., Mizojiri, R., Ito, Y., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708289 · Cited by 101
An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
Mahé, M., Dufour, F., Neyret‐Kahn, H., Moreno-Vega, A. I., Béraud, C., Shi, M., Hamaidi, I., Sánchez‐Quiles, V., Krucker, C., Dorland‐Galliot, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708163 · Cited by 100
MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma
Wang, D., Hashimoto, H., Zhang, X., Barwick, B. G., Lonial, S., Boise, L., Vertino, P. M., & Cheng, X. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1184 · Cited by 93
Targeting MYCN in Pediatric and Adult Cancers
Liu, Z., Chen, S. S., Clarke, S., Veschi, V., & Thiele, C. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.623679 · Cited by 95
Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas
González-Vela, M. D. C., Curiel‐Olmo, S., Derdak, S. V., Beltrán, S., Santibáñez, M., Martı́nez, N., Trujillo, O. A. C., Gut, M., Sánchez-Pacheco, R. E., Almaráz, C., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.08.015 · Cited by 99
MYC multimers shield stalled replication forks from RNA polymerase
Solvie, D., Baluapuri, A., Uhl, L., Fleischhauer, D., Endres, T., Papadopoulos, D., Aziba, A., Gaballa, A., Mikičić, I., Isaakova, E. A., et al. (2022) · Nature · doi:10.1038/s41586-022-05469-4 · Cited by 95
Downregulation of ribosome biogenesis during early forebrain development
Chau, K. F., Shannon, M. L., Fame, R. M., Fonseca, E., Mullan, H., Johnson, M. B., Sendamarai, A. K., Springel, M. W., Laurent, B., & Lehtinen, M. K. (2018) · eLife · doi:10.7554/elife.36998 · Cited by 95
CBFβ-SMMHC Inhibition Triggers Apoptosis by Disrupting MYC Chromatin Dynamics in Acute Myeloid Leukemia
Pulikkan, J. A., Hegde, M. B., Ahmad, H. M., Belaghzal, H., Illendula, A., Yu, J., O’Hagan, K., Ou, J., Müller‐Tidow, C., Wolfe, S. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.048 · Cited by 92
Regulatory mechanisms of PD-L1 expression in cancer cells
Shi, Y. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2226-9 · Cited by 92
SUMO protease SENP1 deSUMOylates and stabilizes c-Myc
Sun, X., Chen, Y., Su, Y., Wang, X., Chauhan, K. M., Liang, J., Daniel, C. J., Sears, R. C., & Dai, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802932115 · Cited by 92
MYC Modulation around the CDK2/p27/SKP2 Axis
Hydbring, P., Castell, A., & Larsson, L. (2017) · Genes · doi:10.3390/genes8070174 · Cited by 92
LAST, a c-Myc-inducible long noncoding RNA, cooperates with CNBP to promote CCND1 mRNA stability in human cells
Cao, L., Zhang, P., Li, J., & Wu, M. (2017) · eLife · doi:10.7554/elife.30433 · Cited by 93
Molecular Crosstalk Between MYC and HIF in Cancer
Li, Y., Sun, X., Qian, D. Z., & Dai, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590576 · Cited by 95
Transcriptional integration of mitogenic and mechanical signals by Myc and YAPPreprint
Croci, O., Fazio, S., Biagioni, F., Donato, E., Cagánová, M., Curti, L., Doni, M., Sberna, S., Aldeghi, D., Biancotto, C., et al. (2017) · Genes & Development · doi:10.1101/gad.301184.117 · Cited by 90
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 86
MYC amplifies gene expression through global changes in transcription factor dynamics
Patange, S., Ball, D. A., Wan, Y., Karpova, T., Girvan, M., Levens, D., & Larson, D. R. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110292 · Cited by 86
Induction of LEF1 by MYC activates the WNT pathway and maintains cell proliferation
Hao, Y.-H., Lafita‐Navarro, M. C., Zacharias, L. G., Borenstein‐Auerbach, N., Kim, M., Barnes, S. D., Kim, J., Shay, J. W., DeBerardinis, R. J., & Conacci‐Sorrell, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0444-1 · Cited by 87
MYC and HIF in shaping immune response and immune metabolism
Gnanaprakasam, J. R., Sherman, J. W., & Wang, R. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.03.004 · Cited by 84
Concepts to Target MYC in Pancreatic Cancer
Wirth, M., Mahboobi, S., Krämer, O. H., & Schneider, G. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0050 · Cited by 81
MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?
Zhang, T., Li, N., Sun, C., Jin, Y., & Sheng, X. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911845 · Cited by 79
Targeting MYC in cancer therapy: RNA processing offers new opportunities
Koh, C. M., Sabò, A., & Guccione, E. (2016) · BioEssays · doi:10.1002/bies.201500134 · Cited by 86
A Time for MYC: Metabolism and TherapyPreprint
Dang, C. V. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031153 · Cited by 78
Human MYC G-quadruplex: From discovery to a cancer therapeutic target
Wang, W., Hu, S., Gu, Y., Yan, Y., Stovall, D. B., Li, D., & Sui, G. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188410 · Cited by 79
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 84
Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment
Hayashi, K., & Anzai, N. (2017) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v9.i1.21 · Cited by 76
Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets
Maharjan, C. K., Ear, P. H., Tran, C. G., Howe, J. R., Chandrasekharan, C., & Quelle, D. E. (2021) · Cancers · doi:10.3390/cancers13205117 · Cited by 73
The role of circadian clock genes in tumors
Li, H.-X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s203144 · Cited by 80
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
Annunziato, S., de Ruiter, J. R., Henneman, L., Brambillasca, C. S., Lutz, C., Vaillant, F., Ferrante, F., Drenth, A. P., van der Burg, E., Siteur, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08301-2 · Cited by 69
An early Myc‐dependent transcriptional program orchestrates cell growth during B‐cell activation
Tesi, A., de Pretis, S., Furlan, M., Filipuzzi, M., Morelli, M. J., Andronache, A., Doni, M., Verrecchia, A., Pelizzola, M., Amati, B. B., et al. (2019) · EMBO Reports · doi:10.15252/embr.201947987 · Cited by 73
The MYC mRNA 3′‐UTR couples RNA polymerase II function to glutamine and ribonucleotide levels
Dejure, F. R., Royla, N., Herold, S., Kalb, J., Walz, S., Ade, C. P., Mastrobuoni, G., Vanselow, J. T., Schlösser, A., Wolf, E., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201796662 · Cited by 75
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma
Manier, S., Huynh, D., Shen, Y. J., Zhou, J., Yusufzai, T. M., Salem, K. Z., Ebright, R. Y., Shi, J., Park, J., Glavey, S. V., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2668 · Cited by 72
c-Src Promotes Tumorigenesis and Tumor Progression by Activating PFKFB3.
Ma, H.-H., Zhang, J., Zhou, L., Wen, S., Tang, H.-Y., Jiang, B., Zhang, F., Suleman, M., Sun, D., Chen, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.005 · Cited by 60
Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake
Zhang, P., Wang, Q., Lin, Z., Yang, P., Dou, K., & Zhang, R. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s235667 · Cited by 68
Dissecting transcriptional amplification by MYC
Nie, Z., Guo, C., Das, S., Chow, C. C., Batchelor, E., Simons, S. S., & Levens, D. (2020) · eLife · doi:10.7554/elife.52483 · Cited by 68
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
Poon, E., Liang, T., Jamin, Y., Walz, S., Kwok, C., Hakkert, A., Barker, K. T., Urban‐Wójciuk, Z., Thway, K., Zeid, R., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134132 · Cited by 69
Oncogene-regulated release of extracellular vesicles
Kilinc, S., Paisner, R., Camarda, R., Gupta, S., Momčilović, O., Kohnz, R. A., Avşaroğlu, B., L’Étoile, N. D., Perera, R. M., Nomura, D. K., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.05.014 · Cited by 70
MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sitesPreprint
See, Y. X., Chen, K., & Fullwood, M. J. (2022) · Genome Research · doi:10.1101/gr.276313.121 · Cited by 64
The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas
D’Andrea, A., Gritti, I., Nicoli, P., Giorgio, M., Doni, M., Conti, A., Bianchi, V., Casoli, L., Sabò, A., Mironov, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11719 · Cited by 64
Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signalsPreprint
Su, Y., Pelz, C., Huang, T., Torkenczy, K. A., Wang, X., Cherry, A. E., Daniel, C. J., Liang, J. B., Nan, X., Dai, M., et al. (2018) · Genes & Development · doi:10.1101/gad.314377.118 · Cited by 64

Authors: Kress, T. R., Sabò, A., & Amati, B.
Affiliations: Italian Institute of Technology (IT)
Corresponding author: Amati, Bruno
ORCID: Sabò, Arianna
Amati, Bruno
Venue: Nature reviews. Cancer
Publisher: Springer Science and Business Media LLC
Published: 2015-09-18
Volume: 15
Issue: 10
Pages: 593-607
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3984
OpenAlex: W1878169898
Cited by: 521
References: 201
Citations by year: 2026: 27 · 2025: 41 · 2024: 52 · 2023: 52 · 2022: 47 · 2021: 57 · 2020: 48 · 2019: 42 · 2018: 58 · 2017: 52 · 2016: 40 · 2015: 5
FWCI: 5.01
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: Associazione Italiana per la Ricerca sul Cancro
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: c-Myc, transcriptional regulation, RNA biogenesis, global transcriptome, differential gene regulation, cell proliferation, carcinogenesis, cellular metabolism, RNA processing, RNA turnover
MeSH terms: Humans, RNA, Messenger, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins c-myc

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MYC: connecting selective transcriptional control to global RNA production

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks